Study S001255

Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07502508
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 60
Start: 2026-04-30
Primary completion: 2027-06
Lead sponsor: Biomea Fusion Inc.
Conditions: Type 2 Diabetes
Interventions: DRUG:icovamenib 100 mg; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control [26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.